The Journal of Phytopharmacology 2024; 13(3):208-211 ; DOI:10.31254/phyto.2024.13303
Comparison and Efficacy Study of In-house Developed Formulation of Fumaria indica (Pitpapra) Against Expensive Market Alternative
Shri Ram Bharat1 , Archana Suyal2 , Brijesh Kumar2 , Suman Kumar Jha3 , Rajeev Saini2
1. Patanjali Ayurved Limited, Patanjali Food & Herbal Park, Padartha, Laksar road, Haridwar, UK, India
2. R & D, Patanjali Natural Coloroma Private Limited, Patanjali Food & Herbal Park, Padartha, Laksar road, Haridwar, UK, India
3. Patanjali Foods Limited, Patanjali Food & Herbal Park, Padartha, Laksar road, Haridwar, UK, India
*Author to whom correspondence should be addressed.
Received: 21st February, 2024 / Accepted: 26th April, 2024 / Published : 1st June, 2024
Extracts of Fumaria species have been traditionally used since ages in India, as they have potential for treatment of skin, scalp diseases, rheumatism, stomach ache and fever mainly because of the presence of many secondary metabolites which makes them pharmacologically valuable, specifically, alkaloids which are considered to have anti-inflammatory and analgesic properties. The purpose of this work was to compare Fumaria indica methanolic formulation with fumaria officinalis methanolic formulation using phytochemical profiling by HPTLC. Which showed that both the species are closely identical to each other. Therefore, this article suggests that Fumaria indica methanolic formulation can be used as an alternative of fumaria officinalis methanolic formulation as both have similarity in phytochemical ingredients when compared. In addition, the In-house developed formulation is economical and efficacious alternative towards market formulation.
Herbal, Formulation, Anti-inflammatory, Fumaria indica, HPTLC
HOW TO CITE THIS ARTICLE
Bharat SR, Suyal A, Kumar B, Jha SK, Saini R. Comparison and efficacy study of in-house developed formulation of Fumaria indica (Pitpapra) against expensive market alternative. J Phytopharmacol 2024; 13(3):208-211. doi: 10.31254/phyto.2024.13303
Creative Commons (CC) License-
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (http://creativecommons.org/licenses/by/4.0/).
Copyright
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.